CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 60 enrolled
Drug / intervention
caffeine/propranolol combination tablet +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01080677
NCT01080677Phase 2Completed

Randomized Double-Blind Study to Evaluate the Dose-Related Efficacy and Safety of Caffeine/Propranolol in the Treatment of Acute Migraine

Stanford University·interventional·Posted Mar 4, 2010·Updated Feb 24, 2017

In Brief

A Phase 2 clinical trial evaluating caffeine/propranolol combination tablet and placebo for Migraine Disorders. Completed, enrolled 60 participants across 1 site.

Detailed Summary

This is a research study to assess the safety of caffeine/propranolol at different dose levels. We want to find out what effects, good and/or bad, it has on patients and their migraines.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 4, 2010
Enrollment StartJan 1, 2007
Primary CompletionSep 1, 2009
Study CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 16.3 years ago

Interventions

caffeine/propranolol combination tabletdrug

caffeine/propranolol combination tablet administered orally once daily

placebodrug

placebo to match caffeine/propranolol combination tablet administered orally once daily